The aim of any study of a potential new drug product is to deliver a safe and effective treatment. Pharmaceutical companies need to achieve these goals in a way that can maximize safety and efficiency, while minimizing costs and negative impacts.
Early phase clinical trials are a critical part of any drug development program. They constitute the first stage, providing vital information on the tolerability, pharmacokinetics, mechanism of action, and safety of a drug. Without this data, drug development cannot proceed as it will be required as the study develops and moves to later phases.
In this white paper, we look at early phase clinical trials and consider the ways in which operators can optimize the study process.